


Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-0C234B5A-5341-4053-A621-C0CE55A2F6A3_4_en-US
DOI: https://doi.org/10.31003/USPNF_M21670_04_01
DOI Ref: s8mub

© 2025 USPC
Do not distribute

Cyproheptadine Hydrochloride



$C_{21}H_{21}N \cdot HCl \cdot 1\frac{1}{2}H_2O$ 350.88

$C_{21}H_{21}N \cdot HCl$ 323.87

Piperidine, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methyl-, hydrochloride, sesquihydrate;

4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride sesquihydrate CAS RN®: 41354-29-4; UNII: NJ82J0F8QC.

Anhydrous CAS RN®: 969-33-5; UNII: 0S9323MCT0.

DEFINITION

Cyproheptadine Hydrochloride contains NLT 98.0% and NMT 102.0% of cyproheptadine hydrochloride ($C_{21}H_{21}N \cdot HCl$), calculated on the anhydrous basis.

IDENTIFICATION

Change to read:

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197K](#) ▲ (CN 1-MAY-2020)
- **B.** The retention time of the cyproheptadine peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• **PROCEDURE**

Solution A: 1 mL/L of [trifluoroacetic acid](#) in [water](#)

Solution B: [Acetonitrile](#) and *Solution A* (38:62)

Solution C: [Acetonitrile](#)

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution B (%)	Solution C (%)
0.0	100	0
6.0	100	0
6.1	15	85
9.0	15	85
9.1	100	0
12	100	0

Diluent: [Acetonitrile](#) and [water](#) (38:62)

Standard solution: 40 µg/mL of [USP Cyproheptadine Hydrochloride RS](#) in *Diluent*. Sonication may be used to aid dissolution.

Sample solution: 40 µg/mL of Cyproheptadine Hydrochloride in *Diluent*. Sonication may be used to aid dissolution.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)**Mode:** LC**Detector:** UV 266 nm**Column:** 4.6-mm × 15-cm; 2.7-μm packing [L60](#)**Flow rate:** 1 mL/min**Injection volume:** 15 μL**System suitability****Sample:** *Standard solution***Suitability requirements****Tailing factor:** NMT 2.0**Relative standard deviation:** NMT 0.73%**Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of cyproheptadine hydrochloride ($C_{21}H_{21}N \cdot HCl$) in the portion of Cyproheptadine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response from the *Sample solution* r_S = peak response from the *Standard solution* C_S = concentration of [USP Cyproheptadine Hydrochloride RS](#) in the *Standard solution* (μg/mL) C_U = concentration of Cyproheptadine Hydrochloride in the *Sample solution* (μg/mL)**Acceptance criteria:** 98.0%–102.0% on the anhydrous basis**IMPURITIES**• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%• **ORGANIC IMPURITIES****Solution A, Solution B, Solution C, Mobile phase, Diluent, and Chromatographic system:** Proceed as directed in the Assay.**Standard stock solution:** 50 μg/mL each of [USP Cyproheptadine Hydrochloride RS](#), [USP Cyproheptadine Related Compound A RS](#), [USP Amitriptyline Related Compound A RS](#), and [USP Cyproheptadine Related Compound C RS](#), prepared as follows. Transfer a suitable quantity of each Reference Standard to an appropriate volumetric flask. Add 38% of the total flask volume of [acetonitrile](#) to dissolve, and then dilute with [water](#) to volume.**Standard solution:** 0.75 μg/mL each of [USP Cyproheptadine Hydrochloride RS](#), [USP Cyproheptadine Related Compound A RS](#), [USP Amitriptyline Related Compound A RS](#), and [USP Cyproheptadine Related Compound C RS](#) from the *Standard stock solution* in *Diluent***Sensitivity solution:** 0.25 μg/mL each of [USP Cyproheptadine Hydrochloride RS](#), [USP Cyproheptadine Related Compound A RS](#), [USP Amitriptyline Related Compound A RS](#), and [USP Cyproheptadine Related Compound C RS](#) from the *Standard stock solution* in *Diluent***Sample solution:** 500 μg/mL of Cyproheptadine Hydrochloride in *Diluent*. Sonication may be used to aid dissolution.**System suitability****Samples:** *Standard solution* and *Sensitivity solution*[NOTE—See [Table 2](#) for the relative retention times.]**Suitability requirements****Resolution:** NLT 3.0 between amitriptyline related compound A and cyproheptadine related compound A, *Standard solution***Relative standard deviation:** NMT 5.0% for cyproheptadine, cyproheptadine related compound A, amitriptyline related compound A, and cyproheptadine related compound C, *Standard solution***Signal-to-noise ratio:** NLT 10 for cyproheptadine hydrochloride, *Sensitivity solution***Analysis****Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of cyproheptadine related compound A, amitriptyline related compound A, and cyproheptadine related compound C in the portion of Cyproheptadine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of each related compound from the *Sample solution* r_S = peak response of each related compound from the *Standard solution* C_S = concentration of the appropriate USP Reference Standard in the *Standard solution* (μg/mL) C_U = concentration of Cyproheptadine Hydrochloride in the *Sample solution* (μg/mL)

Calculate the percentage of any individual unknown impurity in the portion of Cyproheptadine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of any individual unknown impurity from the *Sample solution*

r_S = peak response of cyproheptadine hydrochloride from the *Standard solution*

C_S = concentration of [USP Cyproheptadine Hydrochloride RS](#) in the *Standard solution* (µg/mL)

C_U = concentration of Cyproheptadine Hydrochloride in the *Sample solution* (µg/mL)

Acceptance criteria: See [Table 2](#). Disregard any peak less than 0.05%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Cyproheptadine related compound C	0.7	0.15
Cyproheptadine	1.0	—
Amitriptyline related compound A	2.5	0.15
Cyproheptadine related compound A	2.6	0.15
Any individual unknown impurity	—	0.10
Total impurities	—	0.5

SPECIFIC TESTS

- [WATER DETERMINATION \(921\)](#), *Method I*: 7.0%–9.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.

- [USP REFERENCE STANDARDS \(11\)](#)

[USP Amitriptyline Related Compound A RS](#)

Dibenzosuberone.

$C_{15}H_{12}O$ 208.26

[USP Cyproheptadine Hydrochloride RS](#)

[USP Cyproheptadine Related Compound A RS](#)

5*H*-Dibenzo[*a,d*]cycloheptene.

$C_{15}H_{12}$ 192.26

[USP Cyproheptadine Related Compound C RS](#)

5-(1-Methyl-piperidin-4-yl)-5*H*-dibenzo[*a,d*]cyclohepten-5-ol.

$C_{21}H_{23}NO$ 305.41

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
CYPROHEPTADINE HYDROCHLORIDE	Documentary Standards Support	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 42(3)

Current DocID: GUID-0C234B5A-5341-4053-A621-C0CE55A2F6A3_4_en-US

DOI: <https://doi.org/10.31003/USPNF.M21670.04.01>

DOI ref: [s8muh](#)

OFFICIAL